3rov
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | + | ==Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus== | |
- | + | <StructureSection load='3rov' size='340' side='right' caption='[[3rov]], [[Resolution|resolution]] 2.30Å' scene=''> | |
- | + | == Structural highlights == | |
- | ==Disease== | + | <table><tr><td colspan='2'>[[3rov]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3ROV OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3ROV FirstGlance]. <br> |
- | [[http://www.uniprot.org/uniprot/INS_HUMAN INS_HUMAN]] Defects in INS are the cause of familial hyperproinsulinemia (FHPRI) [MIM:[http://omim.org/entry/176730 176730]].<ref>PMID:3470784</ref><ref>PMID:2196279</ref><ref>PMID:4019786</ref><ref>PMID:1601997</ref> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=IPH:PHENOL'>IPH</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> |
- | + | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DAL:D-ALANINE'>DAL</scene></td></tr> | |
- | ==Function== | + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1znj|1znj]]</td></tr> |
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3rov FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3rov OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3rov RCSB], [http://www.ebi.ac.uk/pdbsum/3rov PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | == Disease == | ||
+ | [[http://www.uniprot.org/uniprot/INS_HUMAN INS_HUMAN]] Defects in INS are the cause of familial hyperproinsulinemia (FHPRI) [MIM:[http://omim.org/entry/176730 176730]].<ref>PMID:3470784</ref> <ref>PMID:2196279</ref> <ref>PMID:4019786</ref> <ref>PMID:1601997</ref> Defects in INS are a cause of diabetes mellitus insulin-dependent type 2 (IDDM2) [MIM:[http://omim.org/entry/125852 125852]]. IDDM2 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.<ref>PMID:18192540</ref> Defects in INS are a cause of diabetes mellitus permanent neonatal (PNDM) [MIM:[http://omim.org/entry/606176 606176]]. PNDM is a rare form of diabetes distinct from childhood-onset autoimmune diabetes mellitus type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Permanent neonatal diabetes requires lifelong therapy.<ref>PMID:17855560</ref> <ref>PMID:18162506</ref> Defects in INS are a cause of maturity-onset diabetes of the young type 10 (MODY10) [MIM:[http://omim.org/entry/613370 613370]]. MODY10 is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.<ref>PMID:18192540</ref> <ref>PMID:18162506</ref> <ref>PMID:20226046</ref> | ||
+ | == Function == | ||
[[http://www.uniprot.org/uniprot/INS_HUMAN INS_HUMAN]] Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. | [[http://www.uniprot.org/uniprot/INS_HUMAN INS_HUMAN]] Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. | ||
- | |||
- | ==About this Structure== | ||
- | [[3rov]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3ROV OCA]. | ||
==See Also== | ==See Also== | ||
*[[Molecular Playground/Insulin|Molecular Playground/Insulin]] | *[[Molecular Playground/Insulin|Molecular Playground/Insulin]] | ||
- | + | == References == | |
- | == | + | <references/> |
- | <references | + | __TOC__ |
- | [[Category: Arvan, P | + | </StructureSection> |
- | [[Category: Brange, J | + | [[Category: Arvan, P]] |
- | [[Category: Dodson, E J | + | [[Category: Brange, J]] |
- | [[Category: Dodson, G G | + | [[Category: Dodson, E J]] |
- | [[Category: Hu, S Q | + | [[Category: Dodson, G G]] |
- | [[Category: Hua, Q X | + | [[Category: Hu, S Q]] |
- | [[Category: Huang, K | + | [[Category: Hua, Q X]] |
- | [[Category: Jia, W H | + | [[Category: Huang, K]] |
- | [[Category: Katsoyannis, P G | + | [[Category: Jia, W H]] |
- | [[Category: Liu, M | + | [[Category: Katsoyannis, P G]] |
- | [[Category: Nakagawa, S H | + | [[Category: Liu, M]] |
- | [[Category: Turkenburg, M | + | [[Category: Nakagawa, S H]] |
- | [[Category: Wan, Z L | + | [[Category: Turkenburg, M]] |
- | [[Category: Wang, S H | + | [[Category: Wan, Z L]] |
- | [[Category: Weiss, M A | + | [[Category: Wang, S H]] |
- | [[Category: Whittaker, J | + | [[Category: Weiss, M A]] |
- | [[Category: Whittingham, J | + | [[Category: Whittaker, J]] |
- | [[Category: Xu, B | + | [[Category: Whittingham, J]] |
+ | [[Category: Xu, B]] | ||
[[Category: Global health]] | [[Category: Global health]] | ||
[[Category: Hormone]] | [[Category: Hormone]] |
Revision as of 10:57, 19 December 2014
Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus
|
Categories: Arvan, P | Brange, J | Dodson, E J | Dodson, G G | Hu, S Q | Hua, Q X | Huang, K | Jia, W H | Katsoyannis, P G | Liu, M | Nakagawa, S H | Turkenburg, M | Wan, Z L | Wang, S H | Weiss, M A | Whittaker, J | Whittingham, J | Xu, B | Global health | Hormone | Insulin fibrillation | Long-acting insulin analog | Receptor binding protein engineering | Stabilizing | Zinc-binding site